Long-term Results of Duodeno-jejunal Bypass in the Treatment of Obesity and Type 2 Diabetes.
Bariatric
Duodenal-jejunal bypass
Endoscopy
Obesity
Type 2 diabetes mellitus
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
received:
11
05
2023
accepted:
06
12
2023
revised:
28
11
2023
medline:
4
3
2024
pubmed:
4
3
2024
entrez:
4
3
2024
Statut:
aheadofprint
Résumé
Obesity and its related severe comorbidities are increasing rapidly. The duodenal-jejunal bypass is an endoscopically implanted device (mimicking the Roux-en-Y gastric bypass) developed to support weight reduction and improve type 2 diabetes control. Retrospective data analysis of consecutive patients undergoing duodenal-jejunal bypass (EndoBarrier®, DJB) implantation between 2013 and 2017 was performed to evaluate safety as well as short- and long-term efficacy. One hundred and twenty-one patients (mean BMI of 43.1 ± 7.2 kg/m Despite an evident rate of adverse events, the DJB shows promise as a weight-loss procedure. Our results show that some patients implanted with the device maintained reduced weight even 24 months after explantation, while many improved T2DM control.
Identifiants
pubmed: 38436919
doi: 10.1007/s11695-023-06979-4
pii: 10.1007/s11695-023-06979-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Eurostat. Over half of adults in the EU are overweight. 2021. https://ec.europa.eu/eurostat/web/products-eurostat-news/-/ddn-20210721-2 .
Adult Obesity Facts. 2020. https://www.cdc.gov/obesity/data/adult.html .
Overweight and obesity. BMI statistics. 2019. https://ec.europa.eu/eurostat/statistics-explained/index.php/Overweight_and_obesity_-_BMI_statistics .
Kral J, et al. Endoscopic treatment of obesity and nutritional aspects of bariatric endoscopy. Nutrients. 2021;13(12):4268. https://doi.org/10.3390/nu13124268 .
doi: 10.3390/nu13124268
pubmed: 34959819
pmcid: 8703836
Okunogbe A, Nugent R, Spencer G, et al. Economic impacts of overweight and obesity: current and future estimates for eight countries. BMJ Glob Health. 2021;6(10):e006351. https://doi.org/10.1136/bmjgh-2021-006351 .
doi: 10.1136/bmjgh-2021-006351
pubmed: 34737167
pmcid: 8487190
Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15:288–98. https://doi.org/10.1038/s41574-019-0176-8 .
doi: 10.1038/s41574-019-0176-8
pubmed: 30814686
Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376:254–66. https://doi.org/10.1056/NEJMra1514009 .
doi: 10.1056/NEJMra1514009
pubmed: 28099824
Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711-U109. https://doi.org/10.1053/j.gastro.2012.02.003 .
doi: 10.1053/j.gastro.2012.02.003
pubmed: 22326434
Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. Cochrane Database Syst Rev (Online). 2014;2014(10):Cd003641. https://doi.org/10.1002/14651858.CD003641.pub4 .
doi: 10.1002/14651858.CD003641.pub4
Gloy VL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347:f5934. https://doi.org/10.1136/bmj.f5934 .
doi: 10.1136/bmj.f5934
pubmed: 24149519
pmcid: 3806364
Buchwald H, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA J Am Med Assoc. 2004;292:1724–37. https://doi.org/10.1001/jama.292.14.1724 .
doi: 10.1001/jama.292.14.1724
Forner PM, Ramacciotti T, Farey JE, et al. Safety and effectiveness of an endoscopically placed duodenal-jejunal bypass device (EndoBarrierA (R)): outcomes in 114 patients. Obes Surg. 2017;27:3306–13. https://doi.org/10.1007/s11695-017-2939-4 .
doi: 10.1007/s11695-017-2939-4
pubmed: 29018990
Koehestanie P, et al. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260:984–92. https://doi.org/10.1097/SLA.0000000000000794 .
doi: 10.1097/SLA.0000000000000794
pubmed: 25072436
Patel N, et al. EndoBarrier (R): a safe and effective novel treatment for obesity and type 2 diabetes? Obes Surg. 2018;28:1980–9. https://doi.org/10.1007/s11695-018-3123-1 .
doi: 10.1007/s11695-018-3123-1
pubmed: 29450844
pmcid: 6018591
SERVICES, U. S. D. O. H. A. H. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. (2017).
Abu Dayyeh BK, et al. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet. 2021;398:1965–73. https://doi.org/10.1016/S0140-6736(21)02394-1 .
doi: 10.1016/S0140-6736(21)02394-1
pubmed: 34793746
Podnos YD, Jimenez JC, Wilson SE, et al. Complications after laparoscopic gastric bypass: a review of 3464 cases. Arch Surg. 2003;138:957–61. https://doi.org/10.1001/archsurg.138.9.957 .
doi: 10.1001/archsurg.138.9.957
pubmed: 12963651
Marczuk P, et al. Effectiveness and safety of Roux-en-Y gastric bypass in elderly patients-systematic review and meta-analysis. Obes Surg. 2019;29:361–8. https://doi.org/10.1007/s11695-018-3546-8 .
doi: 10.1007/s11695-018-3546-8
pubmed: 30353247
Shi X, Karmali S, Sharma AM, et al. A review of laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg. 2010;20:1171–7. https://doi.org/10.1007/s11695-010-0145-8 .
doi: 10.1007/s11695-010-0145-8
pubmed: 20379795
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. https://doi.org/10.1056/NEJMoa2032183 .
doi: 10.1056/NEJMoa2032183
pubmed: 33567185
Ruban A, et al. Duodenal-jejunal bypass liner for the management of type 2 diabetes mellitus and obesity: a multicenter randomized controlled trial. Ann Surg. 2022;275:440–7. https://doi.org/10.1097/SLA.0000000000004980 .
doi: 10.1097/SLA.0000000000004980
pubmed: 34647708
van Rijn S, Roebroek YGM, de Jonge C, et al. Effect of the endobarrier device: a 4-year follow-up of a multicenter randomized clinical trial. Obes Surg. 2019;29:1117–21. https://doi.org/10.1007/s11695-018-03659-6 .
doi: 10.1007/s11695-018-03659-6
pubmed: 30627989
Birkmeyer NJO, et al. Hospital complication rates with bariatric surgery in Michigan. JAMA J Am Med Assoc. 2010;304:435–42. https://doi.org/10.1001/jama.2010.1034 .
doi: 10.1001/jama.2010.1034
Ibrahim Mohamed BK, Barajas-Gamboa JS, Rodriguez J. Endoscopic bariatric therapies: current status and future perspectives. JSLS. 2022;26(1):e2021.00066. https://doi.org/10.4293/JSLS.2021.00066 .
doi: 10.4293/JSLS.2021.00066
pubmed: 35444403
pmcid: 9005302
Hedjoudje A, et al. Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Clin gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2020;18:1043-1053 e1044. https://doi.org/10.1016/j.cgh.2019.08.022 .
doi: 10.1016/j.cgh.2019.08.022
Vargas EJ, et al. Single fluid-filled intragastric balloon safe and effective for inducing weight loss in a real-world population. Clinical Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2018;16:1073-1080 e1071. https://doi.org/10.1016/j.cgh.2018.01.046 .
doi: 10.1016/j.cgh.2018.01.046
Wadden TA, et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity (Silver Spring). 2020;28:529–36. https://doi.org/10.1002/oby.22726 .
doi: 10.1002/oby.22726
pubmed: 32090517
pmcid: 7065111